Literature DB >> 18083927

Control of postnatal bone mass by the zinc finger adapter protein Schnurri-3.

Laurie H Glimcher1, Dallas C Jones, Marc N Wein.   

Abstract

The completed skeleton undergoes continuous remodeling for the duration of adult life. Rates of bone formation by osteoblasts and bone resorption by osteoclasts determine adult bone mass. Abnormalities in either the osteoblast or osteoclast compartment affect bone mass and result in skeletal disorders, the most common of which is osteoporosis, a state of low bone mass. Much is known about the molecular control of bone formation and resorption from rare single gene disorders resulting in elevated or reduced bone mass. Such genetic disorders can be attributed either to osteoclast deficiencies, collectively termed "osteopetrosis," or to intrinsically elevated osteoblast activity, termed "osteosclerosis." However, an increasing need for anabolic therapies to prevent age-induced bone loss has stimulated a search for additional genes that act at the level of the osteoblast to regulate matrix synthesis. Recently, we have discovered a zinc finger adaptor protein called Schnurri-3 (Shn3) that potently regulates adult bone mass. Mice that lack Shn3 have normal skeletal morphogenesis but display profoundly elevated bone mass that increases with age. The molecular mechanism was revealed to be the recruitment of WWP1, a Nedd4 family E3 ubiquitin ligase, by Shn3 to the major transcriptional regulator of the osteoblast, Runx2. In the absence of Shn3, Runx2 degradation by WWP1 is inhibited resulting in increased levels of Runx2 protein and enhanced expression of Runx2 target genes leading to increased osteoblast synthetic activity. Small molecules that inhibit Shn3 or WWP1 may be attractive candidates for the treatment of diseases of low bone mass.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083927     DOI: 10.1196/annals.1402.044

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

Review 1.  Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies.

Authors:  Pierre J Marie
Journal:  Cell Mol Life Sci       Date:  2014-12-09       Impact factor: 9.261

Review 2.  Regulation of gene expression in osteoblasts.

Authors:  Eric D Jensen; Rajaram Gopalakrishnan; Jennifer J Westendorf
Journal:  Biofactors       Date:  2010 Jan-Feb       Impact factor: 6.113

3.  Maintenance of Bone Homeostasis by DLL1-Mediated Notch Signaling.

Authors:  Yukari Muguruma; Katsuto Hozumi; Hiroyuki Warita; Takashi Yahata; Tomoko Uno; Mamoru Ito; Kiyoshi Ando
Journal:  J Cell Physiol       Date:  2017-03-31       Impact factor: 6.384

4.  Selection and Characterization of a DNA Aptamer Specifically Targeting Human HECT Ubiquitin Ligase WWP1.

Authors:  Wesley O Tucker; Andrew B Kinghorn; Lewis A Fraser; Yee-Wai Cheung; Julian A Tanner
Journal:  Int J Mol Sci       Date:  2018-03-07       Impact factor: 5.923

5.  Biomechanical and Bone Material Properties of Schnurri-3 Null Mice.

Authors:  Jochen G Hofstaetter; Barbara M Misof; Dallas C Jones; Ruth Zoehrer; Stéphane Blouin; Christiane Schueler; Eleftherios P Paschalis; Reinhold G Erben; Richard Weinkamer; Klaus Klaushofer; Paul Roschger
Journal:  JBMR Plus       Date:  2019-09-11

6.  Calcium-siRNA Nanocomplexes Optimized by Bovine Serum Albumin Coating Can Achieve Convenient and Efficient siRNA Delivery for Periodontitis Therapy.

Authors:  Yang Wang; Wen Song; Yi Cui; Yang Zhang; Shenglin Mei; Qintao Wang
Journal:  Int J Nanomedicine       Date:  2020-11-20

Review 7.  NEDD4 E3 Ligases: Functions and Mechanisms in Bone and Tooth.

Authors:  Ke Xu; Yanhao Chu; Qin Liu; Wenguo Fan; Hongwen He; Fang Huang
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

Review 8.  E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.

Authors:  N Sévère; F-X Dieudonné; P J Marie
Journal:  Cell Death Dis       Date:  2013-01-17       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.